<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857973</url>
  </required_header>
  <id_info>
    <org_study_id>CEP273</org_study_id>
    <nct_id>NCT01857973</nct_id>
  </id_info>
  <brief_title>Overnight Closed Loop Study in U.S.</brief_title>
  <acronym>OCL</acronym>
  <official_title>In-Clinic Feasibility Study to Observe the Overnight Closed Loop System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter feasibility study. Up to 85 subjects will be enrolled in the study. The
      goal of the study is to demonstrate that the Hybrid Closed Loop (HCL) System is safe to be
      used in an even larger study outside of hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects that have met eligibility criteria will undergo treatment with the hybrid closed
      loop system under various experimental conditions.There is no statistically powered study
      hypothesis testing.

      The investigational centers will be encouraged to include subjects of different ethnicities
      including Hispanic, Native American, and African-American.

      The study is anticipated to last no more than 12 months from investigational center
      initiation to finalization of all data entry and monitoring procedures. Subjects are expected
      to participate for approximately 1- 2 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>subjects undergo treatment with the hybrid closed loop system under various experimental conditions</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform)</measure>
    <time_frame>12 days</time_frame>
    <description>time in euglycemic range (% of Senosr Glucose (SG) 70-180 mg/dL), Phase 3 (closed-loop using the Next Generation Pump (NGP) platform). The experiment was conducted in a monitored setting which lasted for 12 days with the following stressors: missed meal bolus, exercise, missed transmission, Umax (maximum insulin limit) challenges. The study was conducted in a clinic or hotel/house environment for 12 days/11 nights with no dietary or activity restrictions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time in Euglycemic Range - Exploratory A Phase</measure>
    <time_frame>1 day</time_frame>
    <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Exploratory A phase. An overnight closed-loop experiment was performed using the Android Development Platform, software version 2.0 A system's closed-loop algorithm without implementing the upper-limit for insulin delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject With YSI (Yellow Spring Instrument) Dipped Below 50mg/dL - Exploratory B Phase</measure>
    <time_frame>1 day</time_frame>
    <description>The purpose of exploratory B study was to evaluate the efficacy and safety of the insulin upper-limit, Umax. The Umax is a patient-specific parameter which is calculated based on historical data from the pump that includes SG tracings, insulin delivery information, and the carbohydrate inputs from the user. The main objective of Umax is to prevent the user from being severely hypoglycemic (less than 50 mg/dL) by restricting the controller from over-delivery of insulin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject Under-calibrated to Introduce a Persistent Under-reading Sensor Measurement Bias- Phase 1</measure>
    <time_frame>1 day</time_frame>
    <description>Number of subject under-calibrated to introduce a persistent under-reading sensor measurement bias- Phase 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time in Euglycemic Range - Phase 2</measure>
    <time_frame>3 days</time_frame>
    <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time in Euglycemic Range - Phase 4</measure>
    <time_frame>12 days</time_frame>
    <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time in Euglycemic Range - Phase 6</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time in Euglycemic Range - Phase 7</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 7</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Hybrid Closed Loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In-clinic evaluation of the HCL System under various conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid Closed Loop</intervention_name>
    <description>The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
    <arm_group_label>Hybrid Closed Loop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 2-75 years of age at time of screening

          2. A clinical diagnosis of type 1 diabetes as determined by either medical record or
             source documentation from qualified individual to make medical diagnosis

             Exclusion Criteria that are Based on Demands of In-Clinic Study Procedures :

          3. Pump therapy for greater than 6 months with use of real time CGM for any period of
             time (ie. one day) 3 months prior to screening

          4. Adequate venous access as assessed by investigator or appropriate staff

          5. Subject should have an established insulin carbohydrate and insulin sensitivity ratio.

          6. Subject reports at the time of screening that their average fasting glucose is 60
             mg/dL - 200 mg/dL

          7. Subject reports at the time of screening that their average total daily insulin dose
             is 15 units - 110 units. (Insulin pump memory for this information may be used)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMCR Institute, Inc. 700 West El Norte Parkway, Suite 201</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center, 1775 Aurora Court, A140</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine, 2 Church Street South, Suite 404</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia, 617 West Main Street, 4th Floor</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research, 723 SW 10th Street, Suite 100</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <results_first_submitted>March 9, 2018</results_first_submitted>
  <results_first_submitted_qc>October 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2019</results_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCL</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Sensor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 8 phases: Exploratory A, Exploratory B, Phase 1, Phase 2, Phase 3, Phase 4, Phase 6 and Phase 7.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hybrid Closed Loop</title>
          <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exploratory A Phase</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Xploratory B Phase</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 1</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 2</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 3</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 4</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 6</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 7</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject did not meet required BG range</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>drop out after 3 failed attempts</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hybrid Closed Loop</title>
          <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform)</title>
        <description>time in euglycemic range (% of Senosr Glucose (SG) 70-180 mg/dL), Phase 3 (closed-loop using the Next Generation Pump (NGP) platform). The experiment was conducted in a monitored setting which lasted for 12 days with the following stressors: missed meal bolus, exercise, missed transmission, Umax (maximum insulin limit) challenges. The study was conducted in a clinic or hotel/house environment for 12 days/11 nights with no dietary or activity restrictions.</description>
        <time_frame>12 days</time_frame>
        <population>Eight type-1 diabetic subjects participated in this phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Hybrid Closed Loop</title>
            <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time in Euglycemic Range - Phase 3 (Closed-loop Using the NGP Pump Platform)</title>
          <description>time in euglycemic range (% of Senosr Glucose (SG) 70-180 mg/dL), Phase 3 (closed-loop using the Next Generation Pump (NGP) platform). The experiment was conducted in a monitored setting which lasted for 12 days with the following stressors: missed meal bolus, exercise, missed transmission, Umax (maximum insulin limit) challenges. The study was conducted in a clinic or hotel/house environment for 12 days/11 nights with no dietary or activity restrictions.</description>
          <population>Eight type-1 diabetic subjects participated in this phase.</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time in Euglycemic Range - Exploratory A Phase</title>
        <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Exploratory A phase. An overnight closed-loop experiment was performed using the Android Development Platform, software version 2.0 A system's closed-loop algorithm without implementing the upper-limit for insulin delivery.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hybrid Closed Loop</title>
            <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time in Euglycemic Range - Exploratory A Phase</title>
          <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Exploratory A phase. An overnight closed-loop experiment was performed using the Android Development Platform, software version 2.0 A system's closed-loop algorithm without implementing the upper-limit for insulin delivery.</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject With YSI (Yellow Spring Instrument) Dipped Below 50mg/dL - Exploratory B Phase</title>
        <description>The purpose of exploratory B study was to evaluate the efficacy and safety of the insulin upper-limit, Umax. The Umax is a patient-specific parameter which is calculated based on historical data from the pump that includes SG tracings, insulin delivery information, and the carbohydrate inputs from the user. The main objective of Umax is to prevent the user from being severely hypoglycemic (less than 50 mg/dL) by restricting the controller from over-delivery of insulin.</description>
        <time_frame>1 day</time_frame>
        <population>Five out of the eight subjects with YSI dipped below 50mg/dL</population>
        <group_list>
          <group group_id="O1">
            <title>Hybrid Closed Loop</title>
            <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject With YSI (Yellow Spring Instrument) Dipped Below 50mg/dL - Exploratory B Phase</title>
          <description>The purpose of exploratory B study was to evaluate the efficacy and safety of the insulin upper-limit, Umax. The Umax is a patient-specific parameter which is calculated based on historical data from the pump that includes SG tracings, insulin delivery information, and the carbohydrate inputs from the user. The main objective of Umax is to prevent the user from being severely hypoglycemic (less than 50 mg/dL) by restricting the controller from over-delivery of insulin.</description>
          <population>Five out of the eight subjects with YSI dipped below 50mg/dL</population>
          <units>number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject Under-calibrated to Introduce a Persistent Under-reading Sensor Measurement Bias- Phase 1</title>
        <description>Number of subject under-calibrated to introduce a persistent under-reading sensor measurement bias- Phase 1</description>
        <time_frame>1 day</time_frame>
        <population>13 subjects with sensors under-calibrated to introduce a persistent under-reading sensor measurement bias</population>
        <group_list>
          <group group_id="O1">
            <title>Hybrid Closed Loop</title>
            <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject Under-calibrated to Introduce a Persistent Under-reading Sensor Measurement Bias- Phase 1</title>
          <description>Number of subject under-calibrated to introduce a persistent under-reading sensor measurement bias- Phase 1</description>
          <population>13 subjects with sensors under-calibrated to introduce a persistent under-reading sensor measurement bias</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time in Euglycemic Range - Phase 2</title>
        <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 2</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hybrid Closed Loop</title>
            <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time in Euglycemic Range - Phase 2</title>
          <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 2</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time in Euglycemic Range - Phase 4</title>
        <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 4</description>
        <time_frame>12 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hybrid Closed Loop</title>
            <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time in Euglycemic Range - Phase 4</title>
          <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 4</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time in Euglycemic Range - Phase 6</title>
        <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 6</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hybrid Closed Loop</title>
            <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time in Euglycemic Range - Phase 6</title>
          <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 6</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time in Euglycemic Range - Phase 7</title>
        <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 7</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hybrid Closed Loop</title>
            <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time in Euglycemic Range - Phase 7</title>
          <description>Percentage of time in euglycemic range (% of SG 70-180 mg/dL) - Phase 7</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 - 60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hybrid Closed Loop</title>
          <description>In-clinic evaluation of the HCL System under various conditions.
Hybrid Closed Loop: The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Left arm pain due to IV placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Right arm pain due to IV placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Severe hyperglycemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facial petechiae of the eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suiying Huang, Statistician</name_or_title>
      <organization>Medtronic Minimed</organization>
      <phone>818-576-3319</phone>
      <email>suiying.huang@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

